Kalaris Therapeutics Inc. (KLRS)
KLRS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2019-12-31, https://www.sec.gov/Archives/edgar/data/1754068/000156459021005652/0001564590-21-005652-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2019-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KLRS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001754068 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2019
| Line | Value |
|---|---|
| Revenue | $165K |
| Net income | -$23.8M |
| Operating income | -$26.7M |
| Net margin | -14447.9% |
| Operating margin | -16182.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $61.1M |
| Total assets | $139.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 210.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $47.4M cash; operating cash flow -$10.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 23,804,981 (2026-11-03); 18,702,418 a year earlier; 114,063,336 three years earlier. 3y figure adjusted for split (1-for-23 overall). | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest 1-for-23 on 2025-01-16 | Source 2025-01-16 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-04-03 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $6.2M, sold $13K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$11.0M | -$10.6M | $47.4M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$11.5M | -$11.0M | $43.2M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$10.9M | -$11.6M | $34.4M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$10.0M | -$7.1M | $98.1M | $0 | Needs four quarters | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | Not filed | -$11.9M | -$11.3M | $42.4M | $0 | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$11.3M | -$12.5M | $88.4M | $0 | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$10.2M | -$7.4M | $101.0M | $0 | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$22.0M | -$7.9M | $1.6M | $19.5M | Needs four quarters | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-04-13 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 701 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -34.9% |
| 1 month | -29.4% |
| 3 months | -59.4% |
| Year to date | -81.3% |
| 1 year | -70.5% |
| From 52-week high | -85.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELUT | Elutia Inc. | $0.8229 | +0.35% | $36.5M |
| EXOZ | eXoZymes Inc. | $3.99 | +4.18% | $37.1M |
| CRBU | Caribou Biosciences Inc. | $0.3528 | -2.51% | $38.1M |
| TIL | Instil Bio Inc. | $5.75 | -5.43% | $39.0M |
| LONA | LeonaBio Inc. | $3.23 | -6.92% | $30.4M |
| IMA | ImageneBio Inc. | $3.20 | -7.78% | $39.9M |
| INMB | INmune Bio Inc. | $0.9464 | -9.87% | $29.3M |
| CVM | Cel-Sci Corporation | $1.66 | +29.69% | $29.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier